Accéder au contenu
Merck

Tacrine sinusoidal uptake and biliary excretion in sandwich-cultured primary rat hepatocytes.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques (2014-09-17)
Loqman A Mohamed, Amal Kaddoumi
RÉSUMÉ

PURPOSE. The knowledge of hepatic disposition kinetics of tacrine, a first cholinesterase inhibitor was approved by FDA for the treatment of Alzheimer's disease (AD), would help to understand its hepatotoxicity, its therapeutic effect, and improve the management of patients with AD. The current study aims to characterize tacrine hepatic transport kinetics and study the role of organic cation transporters (OCTs), P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP2) in tacrine sinusoidal uptake and biliary excretion. METHODS. Modulation of tacrine hepatic uptake and efflux, biliary excretion index (BEI%), were performed in sandwich-cultured primary rat hepatocytes (SCHs) using transporters inhibitors. Conformation of the integrity of SCHs model was established by capturing images with light-contrast and fluorescence microscopy. RESULTS. Tacrine uptake in SCHs was carrier-mediated process and saturable with apparent Km of 31.5±9.6 µM and Vmax of 908±72 pmol/min/mg protein. Tetraethyl ammonium (TEA), cimetidine and verapamil significantly reduced tacrine uptake with more pronounced effect observed with verapamil which caused 3-fold reduction in tacrine uptake, indicating role for OCTs. Tacrine has a biliary excretion in SCHs with maximum BEI% value of 22.9±1.9% at 10 min of incubation. Addition of MK571 and valspodar decreased the BEI% of tacrine by 40 and 60% suggesting roles for canalicular MRP2 and P-gp, respectively. CONCLUSIONS. Our results show that in addition to metabolism, tacrine hepatic disposition is carrier-mediated process mediated by sinusoidal OCTs, and canalicular MRP2 and P-gp.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Dexaméthasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexaméthasone, ≥98% (HPLC), powder
Sigma-Aldrich
Tetraethylammonium chloride, ≥98% (titration)
Sigma-Aldrich
(±)-Verapamil hydrochloride, ≥99% (titration), powder
Sigma-Aldrich
Selenous acid, 98%
Sigma-Aldrich
Dexaméthasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
USP
Verapamil hydrochloride, United States Pharmacopeia (USP) Reference Standard
USP
Dexaméthasone, United States Pharmacopeia (USP) Reference Standard
Supelco
Dexaméthasone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
9-Amino-1,2,3,4-tetrahydroacridine hydrochloride hydrate, ≥99%
Sigma-Aldrich
Tetraethylammonium chloride, BioUltra, for molecular biology, ≥99.0% (AT)
Sigma-Aldrich
Selenous acid, 99.999% trace metals basis
USP
Fluvoxamine maleate, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Dexaméthasone, meets USP testing specifications
Sigma-Aldrich
Fluvoxamine maleate, solid
Sigma-Aldrich
9-Amino-1,2,3,4-tetrahydroacridine hydrochloride hydrate, ≥99%
Verapamil hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
(±)-Verapamil hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Dexaméthasone, tested according to Ph. Eur.
Supelco
Tetraethylammonium chloride, for electrochemical analysis, ≥99.0%
Supelco
Dexaméthasone, VETRANAL®, analytical standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Dexaméthasone, British Pharmacopoeia (BP) Assay Standard
Dexaméthasone, European Pharmacopoeia (EP) Reference Standard
Fluvoxamine maleate, European Pharmacopoeia (EP) Reference Standard
Fluvoxamine for system suitability, European Pharmacopoeia (EP) Reference Standard